Core Viewpoint -卓正医疗控股有限公司 (卓正医疗) successfully listed on the Hong Kong Stock Exchange, closing at HKD 67.90, a 13.36% increase from its final offering price of HKD 59.90 [1][6]. Group 1: Offering Details - The total number of shares offered globally was 4,750,000, with 475,000 shares allocated for public offering in Hong Kong and 4,275,000 shares for international offering [2]. - The total proceeds from the offering amounted to HKD 284.53 million, with net proceeds after estimated listing expenses of HKD 208.86 million [6][5]. Group 2: Use of Proceeds - The net proceeds will be used to build a professional talent pool for medical AI applications, enhance internal IT systems, upgrade existing medical facilities, establish new ones, and acquire well-performing medical institutions in major cities [6][7]. Group 3: Business Overview - 卓正医疗 operates 19 medical service institutions in China and four general practice clinics in Singapore, focusing on private healthcare services [7]. - Revenue projections for the years ending December 31 are as follows: RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024, with net losses of RMB -221.5 million, -353.2 million, and a projected profit of RMB 80.2 million in 2024 [7][8]. Group 4: Financial Performance - Adjusted net losses for 2022 and 2023 were RMB 123.0 million and RMB 43.6 million, respectively, while adjusted net profits are projected for 2024 and the first eight months of 2025 [10][11]. - Operating cash flows for the years ending December 31 are projected to be RMB 6.9 million in 2022, RMB 123.8 million in 2023, and RMB 171.3 million in 2024 [12]. Group 5: Debt and Financial Challenges - As of the end of 2024, 卓正医疗's total liabilities reached RMB 30.85 billion, with current liabilities increasing from RMB 22.62 billion in 2022 to RMB 27.04 billion by August 2025 [13].

Group 1 - The 2025 China International Chamber of Commerce Council meeting highlighted the positive outlook of multinational companies towards China's "14th Five-Year Plan," viewing it as a key growth opportunity and planning to expand investments in China [1][5] - The Secretary-General of the China-EU Chamber of Commerce emphasized the importance of the "14th Five-Year Plan" and the rapid development in sectors like artificial intelligence and biomedicine, which are attracting foreign investment [1][5] - European companies are experiencing positive growth in China and are planning to deepen their engagement, recognizing the need to adapt to China's evolving market dynamics [1][2] Group 2 - The founder of United Family Healthcare noted a significant shift in patient demographics, with over 90% of patients now being Chinese citizens opting for private healthcare services, reflecting the changing market demands [2] - The Chairman of the Morocco-China Business Council shared insights on successfully entering the Chinese market, emphasizing the importance of understanding local rules and consumer habits for foreign businesses [2][3] - The meeting facilitated discussions on enhancing cooperation between China and Morocco, particularly in supply chain collaboration, indicating a growing interest from Moroccan companies to partner with Chinese firms [3] Group 3 - The meeting was attended by over 900 representatives from various domestic and foreign enterprises and institutions, indicating strong interest in international business collaboration [5] - There is optimism regarding US-China trade relations, with potential for increased cooperation in the healthcare sector, contingent on high-level diplomatic interactions [5]

Summary of Key Points Core Viewpoint - The A-share and Hong Kong stock markets have seen a concentration of new listings, with significant first-day gains for newly listed companies, indicating strong investor interest and market resilience. Group 1: IPO Approvals - Three companies have received IPO approvals this week, all from the Beijing Stock Exchange [2] - Zhejiang Hengdao Technology Co., Ltd. specializes in the research, design, production, and sales of hot runner systems for injection molds, with a major focus on automotive and consumer electronics sectors [3] - Hebi Haichang Intelligent Technology Co., Ltd. focuses on high-performance wiring harness equipment, serving industries such as automotive and renewable energy [5] - Kunshan Hongshida Intelligent Technology Co., Ltd. is engaged in the development and production of intelligent automation equipment for various sectors, including consumer electronics and new energy [6] Group 2: Financial Performance - Hengdao Technology's revenue for 2022-2024 is projected to be 143 million, 168 million, and 234 million yuan, with net profits of 39 million, 49 million, and 69 million yuan respectively [4] - Haichang Intelligent's revenue for the same period is expected to be 520 million, 652 million, and 800 million yuan, with net profits of 108 million, 121 million, and 115 million yuan [5] - Hongshida's revenue is projected to be 397 million, 476 million, and 649 million yuan, with net profits of 30 million, 39 million, and 53 million yuan [7] Group 3: New Listings - "Mingming Hen Mang" (01768.HK), the first stock in the snack retail sector, debuted on January 28, with a first-day closing price increase of 77.52% [9] - Agricultural Technology Company (831038.BJ) listed on the Beijing Stock Exchange, with a first-day closing increase of 1.19% [9] - Zhenstone Co., Ltd. (601112.SH), a leader in clean energy materials, saw its stock price surge by 121.65% on its first day of trading [10] - Medical device company Medela (920119.BJ) also experienced a significant first-day increase of 161.46% [10] Group 4: Filing Dynamics - Eleven companies filed for IPOs in the Hong Kong market this week, with a focus on A+H share expansion [11] - Notable filings include Jucheng Co., a leading non-volatile memory chip designer, and Deyang Co., a leader in energy storage [11] - The trend shows a concentration of hard technology companies seeking to leverage their A-share listings for international financing [12] Group 5: Sector Highlights - Hard technology companies are prominent in the recent IPO filings, with firms like Kunlun New Energy Materials and Coolchip Microelectronics focusing on core material development and AI solutions [12] - Consumer and medical sectors are also active, with companies like Tongrentang and Zhuozheng Medical seeking to expand their service capabilities and market presence [13]

Core Viewpoint - 卓正医疗 is set to launch an IPO from January 29 to February 3, 2026, aiming to raise approximately HKD 2.19 billion through the global offering of 4.75 million shares, targeting the high-end medical service market in China [1][2][4]. Group 1: IPO Details - The company plans to offer 4.75 million shares, with 10% allocated for Hong Kong and 90% for international investors, plus a 15% over-allotment option [1][3]. - The expected price range for the shares is HKD 57.7 to 66.6, with trading anticipated to begin on February 6, 2026 [1][3]. Group 2: Target Market and Strategy - 卓正医疗 focuses on the high-end medical service market, targeting affluent individuals who prefer personalized care [1][3]. - The company has established cornerstone investment agreements with Health Vision, 金域医学检验, 明略科技, and Galaxy Dynasty, securing commitments of USD 11.64 million for share purchases [1][3]. Group 3: Use of Proceeds - The estimated net proceeds of approximately HKD 2.19 billion will be allocated as follows: - 35% for developing a talent pool for medical AI applications and enhancing IT systems [2][4]. - 30% for upgrading existing medical facilities and establishing new ones to broaden patient reach [2][4]. - 25% for acquiring well-performing medical institutions in first-tier and new first-tier cities [2][4]. - 10% for working capital and general corporate purposes [2][4].